GCIQ&A with Lunglife AI's CEO, Paul Pagano
In this interview, Paul Pagano CEO of AI (LLAI ) takes Vox through today’s ‘in line’ H1’23 results and the next steps wrt commercialising its ground-breaking early stage lung cancer blood test.
00:00 - How the LungLB diagnostic works, and what problem it solves.
03:55 - Its accuracy vs the existing standard of care.
05:25 - Size of addressable market.
09:45 - Progress of 425 person validation trial.
11:05 - Significance of the LungLB peer reviewed pilot study & cost-effectiveness health economics report.
13:50 - Commercialisation strategy.
19:45 - Future R&D roadmap.
21:20 - Funding runway & long term opportunity
Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.